These were the highlights last year:
Major highlights during the half year include:
COVID-19 Treatments, Vaccines and Sovereign Manufacturing
During the reporting period IDT continued to operate as an essential service throughout the Victorian
lockdowns. The Company’s activities assisting the Federal Government in its initial COVID-19 response
efforts announced in April 2020 were successfully completed in the half year ended 31 December 2020.
In August 2020, IDT made a formal submission to the Federal Government’s COVID-19 Vaccine and
Treatment Manufacture and Supply Chain Request For Information (RFI). IDT’s RFI submission put
forward the Company’s current and potential facilities and capabilities in relation to the possible
manufacture and supply of COVID-19 treatments and vaccines. IDT’s COVID-19 treatment
manufacturing capabilities include our ability to manufacture Active Pharmaceutical Ingredients (APIs)
as well as finished dosage forms. The Company’s sterile manufacturing suite was also showcased in
IDT’s RFI submission as being potentially capable of producing COVID-19 vaccines. Discussions with
various parties are continuing.
Throughout the COVID-19 crisis, IDT has made several public submissions to the Australian
Government to highlight the sovereign importance of increased local manufacturing of essential
medicines. In December 2020, the Federal Government’s Joint Standing Committee “Inquiry into the
implications of the COVID-19 pandemic for Australia’s foreign affairs, defence and trade”, released its
final report. The Government’s report contained sixteen recommendations which included: The need to
define which critical national systems are essential for Australia to function as a secure and prosperous
first world nation, identifying those elements of the critical national systems with potential foreign supply
chain dependencies and the use of Government procurement to build and sustain sovereign capacity
2
IDT AUSTRALIA LIMITED (ACN 006 522 970)
and to develop plans to move from “at risk” supply chains for critical national systems to sovereign
Australian suppliers.
The Company’s efforts to build momentum for re-shoring the manufacturing of Australia’s essential
medicines have also continued behind the scenes with workshops and industry groups. In late December
2020, the final report from the Institute for Integrated Economic Research Australia (IIER) regarding
Australia’s pharmaceutical supply chain resilience was released. The report highlighted Australia’s
inadequacies and lack of resilience in its healthcare systems, and the need to move away from a “just
in time” market philosophy where Australia now imports over 90% of its medicines.
What news can we expect by end Feb.?
- Forums
- ASX - By Stock
- IDT
- 6 months report - 4 weeks away?
6 months report - 4 weeks away?
Featured News
Add IDT (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.5¢ |
Change
-0.005(4.17%) |
Mkt cap ! $49.43M |
Open | High | Low | Value | Volume |
11.5¢ | 12.0¢ | 11.5¢ | $13.01K | 113.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 276170 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 373973 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 476170 | 0.115 |
10 | 673665 | 0.110 |
5 | 539533 | 0.105 |
1 | 200000 | 0.100 |
1 | 30000 | 0.099 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 373973 | 5 |
0.125 | 200000 | 3 |
0.130 | 151481 | 3 |
0.140 | 471150 | 4 |
0.145 | 152627 | 2 |
Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
Featured News
IDT (ASX) Chart |